These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27456688)

  • 21. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
    Faber R; Zander M; Pena A; Michelsen MM; Mygind ND; Prescott E
    Cardiovasc Diabetol; 2015 Apr; 14():41. PubMed ID: 25896352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generalized allergy due to zinc in insulin treated with zinc-free insulin.
    Ben Ammar I; Ksouri H; Trabelsi N; Mellouli F; Ben Mami F; Dakhli S; Achour A
    Acta Diabetol; 2012 Jun; 49(3):239-41. PubMed ID: 20963448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.
    Davenport C; Mahmood WA; Forde H; Ashley DT; Agha A; McDermott J; Sreenan S; Thompson CJ; McGrath F; McAdam B; Cummins PM; Smith D
    Eur J Endocrinol; 2015 Jul; 173(1):53-61. PubMed ID: 26036811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The insulin analog aspart: a safe alternative in insulin allergy.
    Airaghi L; Lorini M; Tedeschi A
    Diabetes Care; 2001 Nov; 24(11):2000. PubMed ID: 11679473
    [No Abstract]   [Full Text] [Related]  

  • 27. Binding characteristics and crossreactivity of insulin autoantibodies and insulin antibodies directed to three different insulin molecules.
    Jaeger C; Winter S; Eckhard M; Hardt P; Brendel MD; Bretzel RG
    Acta Diabetol; 2008 Sep; 45(3):191-4. PubMed ID: 18493700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
    Buse JB; Garber A; Rosenstock J; Schmidt WE; Brett JH; Videbæk N; Holst J; Nauck M
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1695-702. PubMed ID: 21450987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of insulin antibodies and changes in titers over a long-term period in patients with type 2 diabetes.
    Hattori N; Duhita MR; Mukai A; Matsueda M; Shimatsu A
    Clin Chim Acta; 2014 Jun; 433():135-8. PubMed ID: 24642342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: a retrospective cohort study.
    Kondo Y; Satoh S; Osada UN; Terauchi Y
    Endocr J; 2015; 62(11):971-80. PubMed ID: 26249841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance and allergy to recombinant human insulin.
    Ganz MA; Unterman T; Roberts M; Uy R; Sahgal S; Samter M; Grammer LC
    J Allergy Clin Immunol; 1990 Jul; 86(1):45-51. PubMed ID: 2196303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
    Vilsbøll T; Brock B; Perrild H; Levin K; Lervang HH; Kølendorf K; Krarup T; Schmitz O; Zdravkovic M; Le-Thi T; Madsbad S
    Diabet Med; 2008 Feb; 25(2):152-6. PubMed ID: 18201212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating with liraglutide an obese patient with type 2 diabetes mellitus and hereditary hemochromatosis.
    Tassone F; Baffoni C; Gianotti L; Pellegrino M; Magro G; Cesario F; Maccario M; Borretta G
    Minerva Endocrinol; 2015 Dec; 40(4):331-2. PubMed ID: 25801016
    [No Abstract]   [Full Text] [Related]  

  • 35. Serious diabetic ketoacidosis induced by insulin allergy and anti-insulin antibody in an individual with type 2 diabetes mellitus.
    Takahashi K; Anno T; Takenouchi H; Iwamoto H; Horiya M; Kimura Y; Kawasaki F; Kaku K; Tomoda K; Kaneto H
    J Diabetes Investig; 2022 Oct; 13(10):1788-1792. PubMed ID: 35587395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allergic reactions to human insulin: a review of current knowledge and treatment options.
    Akinci B; Yener S; Bayraktar F; Yesil S
    Endocrine; 2010 Feb; 37(1):33-9. PubMed ID: 19876775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Letter to the Editor: Comment on "The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial" by Kramer C.K., et al.
    Kalra S; Gupta Y
    J Clin Endocrinol Metab; 2015 Nov; 100(11):L116-7. PubMed ID: 26544663
    [No Abstract]   [Full Text] [Related]  

  • 38. Severe insulin-resistant diabetes mellitus associated with hypereosinophilic syndrome.
    Uriuhara A; Morita S; Kuroda S; Fumoto M; Araki S; Aoyama N; Amano K; Hayashi Y; Yokono K; Kasuga M
    Intern Med; 1994 Oct; 33(10):632-6. PubMed ID: 7827382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of a non-insulin dependent diabetic patient with regular spontaneous hypoglycemic attacks, which were due to insulin-binding antibodies induced by human insulin therapy.
    Suzuki K; Hirayama S; Ito S
    Tohoku J Exp Med; 1997 Jun; 182(2):163-73. PubMed ID: 9261935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful Treatment of Insulin Allergy with Desensitization Therapy: A Case Report and Literature Review.
    Elfekih H; Hadjkacem F; Elleuch M; Ghorbel D; Charfi N; Mnif F; Rekik N; Mnif M; Abid M
    Iran J Allergy Asthma Immunol; 2019 Oct; 18(5):572-583. PubMed ID: 32245301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.